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Background
We have developed a vaccine design that utilizes the
unique property of the endoplasmic reticulum chaperon,
heat shock protein (HSP) gp96, to bind antigenic peptides
and deliver them to APCs. Cell-based gp96-Ig vaccines, by
prolonged in vivo secretion of gp96-Ig peptide, imitate
viral replication and provide immune stimuli comparable
to attenuated viruses. In model systems in mice we have
shown that gp96-Ig transfected, antigen expressing cells
secrete gp96-Ig in vivo and stimulate both systemic and
strong mucosal immunity. The aim of our study was to
evaluate safety and systemic and mucosal SIV-immunity
with secreted gp96-Ig-SIV vaccines in non-human pri-
mates.
Methods
Gp96-Ig was generated by replacing the ER retention
sequence KDEL with the IgG1-Fc tag. HEK-293 cells were
transfected with gp96-Ig and with the cDNAs encoding
the SIV antigens gag, pol, env and retanef. Irradiated,
transfected 293 cells that secrete 1, 5 or 50 micrograms
gp96-Ig-SIV-peptide complexes in 24 h, were injected
intraperitoneally in Mamu-A*01+ macaques at 0, 4 and
25 weeks.
Results
After the third immunization the SIV-specific CD8
response was boosted to very high levels in the rectum
and jejunum (30 – 50% tetramer positive cells in the CD8
gate in LPL and IEL). In vaginal IEL gag-specific CD8
responses reached 4%. Tetramer+ cells expressed appro-
priate functional (granzymeB) and migration markers
(CD103). Control macaques immunized with 293 cells
not secreting gp96, showed only background tetramer
binding. The mucosal CD8+ and CD4+ T cells from lam-
ina propria and intraepithelial compartment secrete IL-2
or IFN-gamma or both simultaneously in response to pep-
tide stimulation.
Conclusion
We conclude that the cell secreted gp96-Ig-SIV vaccine is
safe and can induce strong poly-specific, multifunctional
and predominant CD8 responses in mucosal compart-
ments that are thought to be critical for protection from
SIV/HIV infection.
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